RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer

Niederst, Matthew J., Sequist, Lecia V., Poirier, John T., Mermel, Craig H., Lockerman, Elizabeth L., Garcia, Angel R., Katayama, Ryohei, Costa, Carlotta +19 more·2015·Nature Communications
DOI 10.1038/ncomms7377

Cited by (655)

Items 601–655 of 655

  1. Case report: A patient with EGFR L861Q positive adenosquamous lung carcinoma transforming into large cell neuroendocrine cancer after treatment with Almonertinib
    Kele Cheng, Yong Zhu, Ran Sang, Zhongsheng Kuang, Yang Cao · 2025 · Frontiers in Oncology
  2. Genomic Profiling of Extensive Stage Small-Cell Lung Cancer Patients Identifies Molecular Factors Associated with Survival
    Matteo Canale, Milena Urbini, Elisabetta Petracci, Davide Angeli, Gianluca Tedaldi, Ilaria Priano, Paola Cravero, Michele Flospergher, Kalliopi Andrikou, Chiara Bennati et al. · 2025 · Lung Cancer Targets and Therapy
  3. Potentiation of EGFR mutant lung cancer treatment targeting replication stress
    Reshma Bhowmick, John J. Turchi, Shadia Ibrahim Jalal · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
  4. Co-existence of EGFR T790M-acquired lung adenocarcinoma and transformation into small-cell carcinoma in different organs after osimertinib treatment. A case report
    Masahide Takeda, Mariko Asano, Sho Sakamoto, Yuka Izumiya, Yūji Okuda, Kazuhiro Sato, Katsutoshi Nakayama · 2025 · Current Problems in Cancer Case Reports
  5. Current Management Strategies for Patients with Gastrointestinal and Pulmonary Neuroendocrine Tumors
    Yulia V. Mikheeva, Pavel Olegovich Rumyantsev, Konstantin K. Puzakov, Konstantin Yu. Slashchuk, D. D. Omelchuk, Anastasia V. Potapenko, Sergey P. Medvedev · 2025 · Russian Journal of Oncology
  6. Heterogeneity and co-occurrence of resistance mechanisms in EGFR-TKI-induced NSCLC to SCLC transformation: a case report
    Xiaoli Liu, Lijuan Zhang, Guohui Cao, Ke Xu, Juan Wang, Hongtao Zhang · 2025 · AME Case Reports
  7. In Silico Screening and Structural Optimization of Curcumin Derivatives with Potential Anticancer Activity
    Rajanikant Balasaheb Ghotane, Manoj Shrawan Charde, R. D. Chakole, Shashikant V. Bhandari, Yash Shimpi · 2025 · Research Square
  8. Only the strong survive: therapeutic selective pressure drives medulloblastoma leptomeningeal metastasis
    Francis Y. He, Adrienne Ann Boire · 2025 · Molecular Oncology
  9. Molecular Pathology of Lung Tumors
    Helmut Popper · 2025 · Springer eBooks
  10. Lung Tumors
    Helmut Popper · 2025 · Springer eBooks
  11. Additional file 1 of USP13 drives lung squamous cell carcinoma by switching lung club cell lineage plasticity
    Juntae Kwon, Zhang, Jinmin, Boram Mok, Samuel Allsup, Kim, Chul, Toretsky, Jeffrey, Cecil Han · 2023 · Figshare
  12. Additional file 1 of Transformation to small cell lung cancer is irrespective of EGFR and accelerated by SMAD4-mediated ASCL1 transcription independently of RB1 in non-small cell lung cancer
    Xi Ding, Shi, Min-xing, Liu, Di, Cao, Jing-xue, Zhang, Kai-xuan, Zhang, Run-dong, Zhang, Li-ping, Kaixing Ai, Bo Su, Zhang, Jie · 2024 · Figshare
  13. Additional file 1 of Genomic features of Chinese small cell lung cancer
    Liu, Jun, Zhao, Zhuxiang, Wei, Shuquan, Li, Binkai, Zhao, Ziwen · 2022 · Figshare
  14. Additional file 1 of Genomic and transcriptomic profiling of combined small-cell lung cancer through microdissection: unveiling the transformational pathway of mixed subtype
    Ma, Wenjuan, Zhou, Ting, Song, Mengmeng, Liu, Jiaqing, Chen, Gang, Jianhua Zhan, Ji, Liyan, Fan Luo, Gao, Xuan, Pansong Li et al. · 2024 · Figshare
  15. Additional file 2 of Genomic and transcriptomic profiling of combined small-cell lung cancer through microdissection: unveiling the transformational pathway of mixed subtype
    Ma, Wenjuan, Zhou, Ting, Song, Mengmeng, Liu, Jiaqing, Chen, Gang, Jianhua Zhan, Ji, Liyan, Fan Luo, Gao, Xuan, Pansong Li et al. · 2024 · Figshare
  16. Additional file 2 of USP13 drives lung squamous cell carcinoma by switching lung club cell lineage plasticity
    Juntae Kwon, Zhang, Jinmin, Boram Mok, Samuel Allsup, Kim, Chul, Toretsky, Jeffrey, Cecil Han · 2024 · Figshare
  17. Additional file 3 of USP13 drives lung squamous cell carcinoma by switching lung club cell lineage plasticity
    Juntae Kwon, Zhang, Jinmin, Boram Mok, Samuel Allsup, Kim, Chul, Toretsky, Jeffrey, Cecil Han · 2024 · Figshare
  18. Additional file 1 of Liquid biopsy as an option for predictive testing and prognosis in patients with lung cancer
    Alvida Qvick, Bianca Stenmark, Carlsson, Jessica, Johan Isaksson, Christina Karlsson, Gisela Helenius · 2021 · Figshare
  19. Additional file 4 of USP13 drives lung squamous cell carcinoma by switching lung club cell lineage plasticity
    Juntae Kwon, Zhang, Jinmin, Boram Mok, Samuel Allsup, Kim, Chul, Toretsky, Jeffrey, Cecil Han · 2024 · Figshare
  20. Additional file 5 of USP13 drives lung squamous cell carcinoma by switching lung club cell lineage plasticity
    Juntae Kwon, Zhang, Jinmin, Boram Mok, Samuel Allsup, Kim, Chul, Toretsky, Jeffrey, Cecil Han · 2024 · Figshare
  21. Additional file 2 of Comprehensive molecular characterization of lung tumors implicates AKT and MYC signaling in adenocarcinoma to squamous cell transdifferentiation
    Àlvaro Quintanal-Villalonga, Taniguchi, Hirokazu, Yingqian Ada Zhan, Maysun Hasan, Shweta S. Chavan, Meng, Fanli, Fathema Z. Uddin, Viola Allaj, Parvathy Manoj, Nisargbhai Shah et al. · 2021 · Figshare
  22. Stem cell control and cancer initiation by an autocrine, injury-activated Igf complex
    Yue Zhang, Youcef Ouadah, Yin Liu, Maya E. Kumar, Makenna M. Morck, Mark A. Krasnow · 2026 · bioRxiv (Cold Spring Harbor Laboratory)
  23. Radiation Therapy to Prolong Systemic Therapy Benefit Across Solid Tumors
    Abdul Zakkar, Laila A. Gharzai, Mohamed E. Abazeed · 2026 · Advances in Oncology
  24. UHRF1 drives subtype-independent aggressiveness and immune evasion in small cell lung cancer through PRC2 interactions
    Yijun Gu, Jamie-Jean De La Torre, Yasamin Fazeli, J. Mateo Valenzuela, Frederick Guzman, Roberto Tinoco, Claudia A. Benavente · 2026 · iScience
  25. Tyrosine phosphoproteome profiling identifies cell-intrinsic signals limiting the efficacy of tyrosine kinase inhibitor therapies
    C. T. Flower, Forest M. White · 2026 · Proceedings of the National Academy of Sciences of the United States of America
  26. Cartographie du phosphoprotéome régulé par les isoformes du PI3K de classe I dans le cancer du pancréas
    Célia Cintas · 2017 · theses.fr (ABES)
  27. Longitudinal, Retrospective Use of a Circulating Tumor DNA Methylation Signature Successfully Captures Small Cell Evolution in a Patient With Metastatic EGFR-Mutant Non–Small Cell Lung Cancer
    Tejas Patil, Amy Guimarães-Young, Jill Tsai, Dara L. Aisner, Leslie A. Bucheit, Anton Valouev · 2026 · JCO Precision Oncology
  28. Compréhension des étapes précoces de la résistance adaptative aux inhibiteurs de tyrosine kinase de l'EGFR dans les cancers bronchiques
    Sarah Figarol · 2020 · theses.fr (ABES)
  29. Une nouvelle stratégie thérapeutique pour prolonger la réponse du cancer bronchique aux inhibiteurs d’EGFR en prévenant l’émergence des cellules résistantes
    Lisa Brunet · 2021 · theses.fr (ABES)
  30. Molecular mechanisms of drug-tolerance to EGFR-targeted therapies in lung adenocarcinoma
    Camille Léonce · 2021
  31. Caractérisation des facteurs de variation de l’efficacité et de la toxicité des thérapies anticancéreuses dans le cancer bronchique non à petites cellules
    David Barthélémy · 2023
  32. Discovery of novel 1,2,4-triazoles derivatives acting as NF1 activators against cervical cancer
    Yao Yin, Zhibing Song, Luqi Wang, Sami Karam, Yijing Zhang, Davor Margetić, Peiran Chen, Yingyuan Peng, Yijia Yan, Zhi-Long Chen · 2026 · Bioorganic & Medicinal Chemistry
  33. ELMO2 is a therapeutic vulnerability in mesenchymal-like and drug-resistant non-small cell lung cancer
    Min Li, Ying-Xian Xue, Yu-i Chang, Fan Xu, Feizhen Wu, Xin-Jian Tian, Jie Hu, Yi-Jun Song, Xu-Fen Yu, Fei Zhou et al. · 2026 · Nature Communications
  34. Unmasking biomarkers in small cell lung cancer: implication for precision oncology
    Devshree Parganiha, Mohit Joshi, Sivaramasundaram Sankarasubramanian, Sharanya V Pandit, Harishmitha Nagaraj, Naveenkumar Perumal · 2026 · Frontiers in Oncology
  35. Methylation–based liquid biopsy facilitates early detection of small cell transformation in ALK -rearranged non–small cell lung cancer
    Jinesh Gheeya, Raj Singh, Mingjia Li, Saman Seyed Ahmadian, Konstantin Shilo, Triparna Sen, Christian D. Rolfo, David Paul Carbone, Dwight H. Owen, David R. Gandara · 2026 · The Oncologist
  36. Risk Stratification and Strategies Towards Front-Line Therapy of EGFR-Mutant NSCLC: A Narrative Review
    Kyle Taing, Hei Yeung Lam, Robert C. Hsu · 2026 · Cancers
  37. Basic and Translational Research Advances in NSCLC
    Rajal Sharma, Katerina A. Politi · 2026 · The Cancer Journal
  38. Developmentally constrained plasticity as a therapeutic vulnerability in cancer
    Jun Xian, Yuanxiang Yang, Wei-Ling Li, Ming Liu, Xiao-Feng Zhang · 2026 · Neoplasia
  39. Mycoplasma infection drives EGFR-TKI resistance through convergent transcriptomic reprogramming in non-small cell lung cancer
    Bing Wang, Valentina Donati, Alessandro Gregori, Alessandro Leonetti, Aldo Pastore, Dongmei Deng, Elisa Giovannetti · 2026 · iScience
  40. Genomic Profiling, Risk Stratification, and Post-Transformation Treatment Outcomes in Patients with Transformed Small-Cell Lung Cancer: A Multicenter Analysis
    Ruolin Gao, Zhenxiang Li, Jie Huang, Jun Zhao, Yan Wang, Qinxiang Guo, Guangchuan Deng, Hua Bai, Xu Yang, Jianchun Duan et al. · 2026 · Lung Cancer
  41. Epigenetic reprogramming of lineage switching in cancer
    Ezgi Boyvatlı, Burcu Akman, Ezgi Bağırsakçı, Neşe Atabey, Serap Erkek · 2026 · FEBS Letters
  42. Polycomb scaffolding subunit EED supports the SCLC neuroendocrine identity and EGFR-mutant LUAD-to-SCLC transformation
    Yixiang Li, Yasmin Nabil Laimon, Hyeonseo Cho, Marina Vivero, Gabriel Roberti De Oliveira, Maxwell D. Seager, Andrew Delcea, Varunika Savla, Yuting Chen, Yavuz T. Durmaz et al. · 2026 · Journal of Clinical Investigation
  43. Advanced and underlying therapeutic strategies in transformed small cell lung cancer
    Ming‐Feng Wei, Zheng Li, Kaiyuan Zhu, Shixiang Guo, Lefei Hu, Fuzhi Yang, Xiaoyu Chen, Xuelin Zhang, Shuai Jiang, Xunxia Zhu et al. · 2026 · Frontiers in Medicine
  44. Targeting EGFR in lung cancer: lessons in signal transduction and treatment-induced mutagenesis
    Arturo Simoni Nieves, Marieke Van Daele, Harrison B. Konsker, Yosef Yarden · 2026 · Philosophical Transactions of the Royal Society B Biological Sciences
  45. Transcriptomic profiling of lineage transformation and actionable therapy opportunities in EGFR-mutant non-small cell lung cancer evolving to small cell lung cancer
    Hui Yu, Meichen Li, Xiaodie Li, Mingjie Yu, Yin Pan, Jingping Yun, Likun Chen · 2026 · Journal of Translational Medicine
  46. Mechanisms of acquired resistance to osimertinib in EGFR T790M-Positive lung adenocarcinoma
    Kefan Cui, Renjie Zhu, Jingmeng Li · 2026 · Frontiers in Genetics
  47. Lineage plasticity and immune invisibility in primary SCLC and LUAD-to-SCLC transformation: antigen presentation loss and therapeutic redirection
    Hongying Xu, Benhua Li, Jun Yang, Xin Tang · 2026 · Frontiers in Immunology
  48. Genes, fuel, and fate in lung cancer
    Julia S. Scott, Catrin Lutz, Stefan Preković · 2026 · Biochemical Society Transactions
  49. Cell plasticity in cancer and therapy resistance.
    Yoojeong Seo, Jin-Ho Jang, Jae-Il Park · 2026 · Experimental and Molecular Medicine
  50. Beyond target presence: A cross-cancer contextual framework for siRNA therapeutics in solid tumors
    Na Zhao, Yang Zhang, Chao Qian, 张华巍, Lei Wang · 2026 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
  51. Metabolic control of methylation landscapes in cancer growth and plasticity: targeting the epigenetic–metabolic axis with natural compounds and emerging therapies
    Qi Liu, Ying Yu, Wenbo Li, Xinxu Chen, Zekai Shi, Gang Li, Shibo Wei, Zongjian Luo · 2026 · Frontiers in Cell and Developmental Biology
  52. Changes in HER2 protein expression before and after EGFR TKI therapy in EGFR-mutant non-small cell lung cancer: a real world paired-biopsy study
    Jinyong Kim, Yurimi Lee, Sehhoon Park, Hyun Ae Jung, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Yoon-La Choi, Myung‐Ju Ahn · 2026 · Lung Cancer
  53. BindingDB Entry 50017046: Emerging Approaches to Overcome Acquired Drug Resistance Obstacles to Osimertinib in Non-Small-Cell Lung Cancer.
    BindingDB · 2023 · UC San Diego
  54. BindingDB Entry 50003219: Recent updates on third generation EGFR inhibitors and emergence of fourth generation EGFR inhibitors to combat C797S resistance.
    BindingDB · 2020 · UC San Diego
  55. BindingDB Entry 50015026: Design, synthesis and biological evaluation of aminopyrimidine derivatives bearing a 4,5,6,7-tetrahydrothieno [3,2-c]pyridine as potent EGFR inhibitors.
    BindingDB · 2023 · UC San Diego